Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | Director | May 05, 2026 | May 07, 2026 |
| Encompass Health CorpEHC · Entity 3460 | Director | July 15, 2026 | July 16, 2026 |
| Pear Therapeutics, Inc.PEAR · Entity 114512 | Director | February 15, 2023 | February 17, 2023 |
| Walgreens Boots Alliance, Inc.WBA · Entity 16467 | Director | August 13, 2025 | August 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BAXTER INTERNATIONAL INC
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 34,994 |
Reported balance
After 2026-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-05 · Grant · Acquired 12,836 · Balance 34,994 F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2: Total includes the automatic reinvestment of dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.
F2: Total includes the automatic reinvestment of dividends.
Encompass Health Corp
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Encompass Health Common StockSEC Table I · non-derivative | Direct | 22,972 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 40 · Balance 22,972 F1: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
Pear Therapeutics, Inc.
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 66,666 |
Reported balance
After 2023-02-15 transaction · row 1
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 66,666 · Balance 66,666 |
Walgreens Boots Alliance, Inc.
Report date August 13, 2025 · Filed August 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,961 |
Reported balance
After 2025-08-13 transaction · row 1
1 source rowRow 1 · 2025-08-13 · Grant · Acquired 16,820 · Balance 37,961 F1: Annual share grant issued as non-employee director compensation under the Amended and Restated Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan in arrears with respect to services rendered over the course of the prior year. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual share grant issued as non-employee director compensation under the Amended and Restated Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan in arrears with respect to services rendered over the course of the prior year.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Hill-Rom Holdings, Inc.
Report date December 13, 2021 · Filed December 15, 2021
Section 16 reporting ended · disclosed 2021-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (03/14/2017)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-13 · Disposition to issuer · Disposed 2,762 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F2: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (03/07/2018)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-13 · Disposition to issuer · Disposed 2,184 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F2: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (03/06/2019)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-13 · Disposition to issuer · Disposed 1,762 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F2: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (02/26/2020)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-12-13 · Disposition to issuer · Disposed 1,870 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F2: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (03/11/2021)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-12-13 · Disposition to issuer · Disposed 1,798 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F2: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2021-12-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock.
F2: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 16, 2026 20:18 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 40 | $0.00 | $0.00 |
DisclosureSEC source: 0000785161-26-000174 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,972 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment. Read SEC document |
| May 07, 2026 Filed May 11, 2026 15:31 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 1,634 | $0.00 | $0.00 |
DisclosureSEC source: 0000785161-26-000132 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,932 F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:20 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 12,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032184 · wk-form4_1778185209.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,994 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 18:40 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 39 | $0.00 | $0.00 |
DisclosureSEC source: 0000785161-26-000111 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,298 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 21:21 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 40 | $0.00 | $0.00 |
DisclosureSEC source: 0000785161-26-000008 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,259 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 19:36 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0000785161-25-000098 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,219 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 17:59 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | GrantCommon Stock | 16,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001618921-25-000077 · wk-form4_1755295192.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,961 F1 · kind: Annual share grant issued as non-employee director compensation under the Amended and Restated Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan in arrears with respect to services rendered over the course of the prior year. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 18:17 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 34 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-019255 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,186 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| May 06, 2025 Filed May 8, 2025 20:27 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 7,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-008902 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,850 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| May 01, 2025 Filed May 2, 2025 18:24 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 1,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013121 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,152 F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:48 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-012145 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,728 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $102.30. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 19:55 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 36 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-001418 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,695 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 20:57 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | GrantCommon Stock | 21,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001618921-24-000129 · wk-form4_1730858260.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,141 F1 · kind: Shares issued as non-employee director compensation under the Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan (including the applicable election forms thereunder). Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 17:16 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-025666 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,659 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:15 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020574 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,624 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| May 07, 2024 Filed May 9, 2024 20:34 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 5,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009784 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,278 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| May 02, 2024 Filed May 3, 2024 17:16 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 1,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014081 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,589 F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 21:01 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013019 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,611 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 20:28 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 37 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-001399 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,578 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 16, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $71.45. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 16:18 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | SaleCommon Stock | 15,209 | $23.05 | $350,567.45 |
DisclosureSEC source: 0001618921-24-000008 · wk-form4_1705612712.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 19:18 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | GrantCommon Stock | 9,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001618921-23-000090 · wk-form4_1699053485.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,209 F1 · kind: Shares issued as non-employee director compensation under the Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan (including the applicable election forms thereunder). Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 21:24 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 42 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-026021 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,541 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 16, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $63.77. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 17, 2023 Filed Jul 18, 2023 18:00 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 39 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020915 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,499 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $67.54. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| May 04, 2023 Filed May 8, 2023 16:55 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 2,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014805 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,460 F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan. Read SEC document |
| May 02, 2023 Filed May 4, 2023 20:34 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 4,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-010211 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,099 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 17:16 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 37 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-013204 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,075 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.39. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:11 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantClass A Common Stock | 66,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004036 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,666 Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 16:50 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 37 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-001749 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,038 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 18:11 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | SaleCommon Stock | 16,570 | $39.89 | $660,927.59 |
DisclosureSEC source: 0001618921-22-000095 · wf-form4_166907227504727.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,515 Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 19:13 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | GrantCommon Stock | 5,515 | $0.00 | $0.00 |
DisclosureSEC source: 0001618921-22-000075 · wf-form4_166751718079532.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,085 F1 · kind: Shares issued as non-employee director compensation under the Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 15:13 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 46 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024122 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,001 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 17, 2022, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $48.81. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 21:12 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-019605 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,432 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 20, 2022, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $49.19. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:12 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014977 · form4.xml · derivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR common stock. F2 · derivative.exercise_date: The restricted stock units shall vest and settle as to 100% of the shares upon the Reporting Person's cessation of Service Relationship (as defined in the Issuer's 2021 Stock Option and Incentive Plan) that qualifies as a "separation from service" within the meaning of Section 409A of the Internal Revenue Code (the "Separation Date"), provided that the Separation Date occurs on or after June 14, 2023 (and for the avoidance of doubt, if the Separation Date occurs prior to June 14, 2023, the restricted stock units shall expire unvested). F2 · derivative.expiration_date: The restricted stock units shall vest and settle as to 100% of the shares upon the Reporting Person's cessation of Service Relationship (as defined in the Issuer's 2021 Stock Option and Incentive Plan) that qualifies as a "separation from service" within the meaning of Section 409A of the Internal Revenue Code (the "Separation Date"), provided that the Separation Date occurs on or after June 14, 2023 (and for the avoidance of doubt, if the Separation Date occurs prior to June 14, 2023, the restricted stock units shall expire unvested). Read SEC document |
| May 05, 2022 Filed May 9, 2022 20:21 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 2,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013836 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,347 F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:25 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 2,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-011690 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,451 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 18:04 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 40 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012253 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,121 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 18, 2022, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $71.41. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:16 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 46 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-001736 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,081 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 18, 2022, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $61.63. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 21:10 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 743 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-048121 · doc4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743 F1 · shares: The reporting person received a grant of 743 fully vested shares of common stock of Baxter International Inc. subject to the terms and conditions of the applicable grant. F1 · price: The reporting person received a grant of 743 fully vested shares of common stock of Baxter International Inc. subject to the terms and conditions of the applicable grant. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:40 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerRestricted Stock Units (03/11/2021) · Derivative | 1,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-013220 · marketforms-54639.xml · derivative · entry 6 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,798 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F2 · price: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. F2 · derivative.exercise_date: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. F2 · derivative.expiration_date: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:40 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerRestricted Stock Units (02/26/2020) · Derivative | 1,870 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-013220 · marketforms-54639.xml · derivative · entry 5 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,870 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F2 · price: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. F2 · derivative.exercise_date: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. F2 · derivative.expiration_date: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:40 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerRestricted Stock Units (03/06/2019) · Derivative | 1,762 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-013220 · marketforms-54639.xml · derivative · entry 4 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,762 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F2 · price: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. F2 · derivative.exercise_date: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. F2 · derivative.expiration_date: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:40 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerRestricted Stock Units (03/07/2018) · Derivative | 2,184 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-013220 · marketforms-54639.xml · derivative · entry 3 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,184 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F2 · price: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. F2 · derivative.exercise_date: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. F2 · derivative.expiration_date: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:40 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerRestricted Stock Units (03/14/2017) · Derivative | 2,762 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-013220 · marketforms-54639.xml · derivative · entry 2 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,762 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F2 · price: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. F2 · derivative.exercise_date: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. F2 · derivative.expiration_date: Pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 22:26 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 110,430 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001062993-21-012398 · form4.xml · derivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,430 Underlying: Common Stock · 110,430 shares Expires 2030-12-18 F2 · price: Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 75,000 shares of common stock of Private Pear for $1.77 per share. F1 · derivative.exercise_date: 33% of the shares underlying the option vested or shall vest on December 1, 2021, an additional 33% of the shares vested or shall vest on December 1, 2022, and an additional 34% of the shares vested or shall vest on December 1, 2023. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 20:04 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | SaleCommon Stock | 2,725 | $47.16 | $128,497.38 |
DisclosureSEC source: 0001618921-21-000125 · wf-form4_163771584276464.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,570 Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 19:44 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | GrantCommon Stock | 4,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001618921-21-000109 · wf-form4_163598305440393.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,295 F1 · kind: Shares issued as non-employee director compensation under the Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 13:35 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 42 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-027259 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,035 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2021, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $67.62. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 18:56 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-022102 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,993 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2021, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $79.89. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| May 06, 2021 Filed May 10, 2021 16:16 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 1,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015992 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,958 F1 · shares: Award of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 13:50 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 28 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-013959 · form4.xml · nonDerivative · entry 1 SCHLICHTING NANCY M · CIK 0001376358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,201 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2021, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $82.66. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.